Charles River Laboratories Intl. Inc vs Ishares Msci Thailand Etf — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.34B), while Ishares Msci Thailand Etf trades at $71.14 (market cap $426.06M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 33.7× Ishares Msci Thailand Etf's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Ishares Msci Thailand Etf nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Ishares Msci Thailand Etf for 65 Days on average.
| CRL | THD | |
|---|---|---|
Market Cap | $14.34B | $426.06M |
Volume | 1,242,136 | 93,387 |
Sector | Health | Broad Market / Factor |
52-Week High | $310.77 | $75.06 |
52-Week Low | $149.93 | $57.86 |
Typical Hold Time | 33 Days | 65 Days |
Enterprise Value | $17.17B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298.00, down 2.28% on the day, but maintains a bullish technical outlook with strong analyst support. The stock has consistently beaten earnings expectations in recent quarters, though profitability metrics show challenges with negative net income margins and ROE. Recent investor day presentations highlighted a refreshed growth strategy targeting 5-7% organic revenue growth and $300 million in cost savings by 2030, providing fundamental catalysts.
While CRL faces profitability headwinds and premium valuation multiples, strong analyst consensus (73% buy ratings) and a $305.50 price target suggest upside potential. Key risks include execution on margin improvement targets and ongoing cost volatility in non-human primate services. The combination of technical strength, strategic initiatives, and Wall Street support creates a favorable risk-reward profile for growth-oriented investors.
THD trades at $71.80, down 0.15% with a bearish technical outlook as moving averages signal selling pressure. Short interest surged 90.6% in September 2026, indicating growing skepticism. The ETF has delivered strong 38% returns over the past year, outperforming ASEAN peers, but faces headwinds from potential profit-taking in AI-exposed holdings like Delta Electronics.
The outlook is cautious given elevated short interest and technical weakness. While THD benefits from Thailand's AI hardware exposure, concentration risk and regional capital outflows pose challenges. Investors should weigh strong historical performance against near-term sentiment pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →